ES2289137T3 - Utilizacion de conjugados de acido o acidos grasos con un acido biliar o una sal biliar. - Google Patents
Utilizacion de conjugados de acido o acidos grasos con un acido biliar o una sal biliar. Download PDFInfo
- Publication number
- ES2289137T3 ES2289137T3 ES02761957T ES02761957T ES2289137T3 ES 2289137 T3 ES2289137 T3 ES 2289137T3 ES 02761957 T ES02761957 T ES 02761957T ES 02761957 T ES02761957 T ES 02761957T ES 2289137 T3 ES2289137 T3 ES 2289137T3
- Authority
- ES
- Spain
- Prior art keywords
- acid
- bile
- fatty
- liver
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002253 acid Substances 0.000 title claims abstract description 28
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 14
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 14
- 239000000194 fatty acid Substances 0.000 title claims abstract description 14
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 11
- 150000003839 salts Chemical class 0.000 title description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 15
- 239000003833 bile salt Substances 0.000 claims abstract description 13
- 239000003613 bile acid Substances 0.000 claims abstract description 11
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 238000010521 absorption reaction Methods 0.000 claims abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims abstract description 4
- 150000002148 esters Chemical class 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000007787 solid Substances 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 8
- 210000000941 bile Anatomy 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 3
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 abstract description 15
- 208000010706 fatty liver disease Diseases 0.000 abstract description 14
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 14
- 210000004185 liver Anatomy 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 230000000927 lithogenic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL142650 | 2001-04-17 | ||
| IL142650A IL142650A (en) | 1998-04-08 | 2001-04-17 | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2289137T3 true ES2289137T3 (es) | 2008-02-01 |
Family
ID=11075322
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02761957T Expired - Lifetime ES2289137T3 (es) | 2001-04-17 | 2002-04-15 | Utilizacion de conjugados de acido o acidos grasos con un acido biliar o una sal biliar. |
| ES07002485T Expired - Lifetime ES2328966T3 (es) | 2001-04-17 | 2002-04-15 | Uso de conjugados de acido biliar o sal biliar con acido graso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07002485T Expired - Lifetime ES2328966T3 (es) | 2001-04-17 | 2002-04-15 | Uso de conjugados de acido biliar o sal biliar con acido graso. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7501403B2 (enExample) |
| EP (2) | EP1790346B1 (enExample) |
| JP (1) | JP4324706B2 (enExample) |
| KR (1) | KR100883080B1 (enExample) |
| CN (1) | CN1259918C (enExample) |
| AT (2) | ATE432705T1 (enExample) |
| AU (2) | AU2002307771B2 (enExample) |
| BR (1) | BR0208924A (enExample) |
| CA (2) | CA2703688C (enExample) |
| CY (1) | CY1106853T1 (enExample) |
| CZ (2) | CZ309042B6 (enExample) |
| DE (2) | DE60220775T2 (enExample) |
| DK (2) | DK1379254T3 (enExample) |
| EA (1) | EA007565B1 (enExample) |
| ES (2) | ES2289137T3 (enExample) |
| HU (1) | HU230548B1 (enExample) |
| IL (1) | IL142650A (enExample) |
| MX (1) | MXPA03009553A (enExample) |
| NO (2) | NO333910B1 (enExample) |
| NZ (1) | NZ528868A (enExample) |
| PL (2) | PL205057B1 (enExample) |
| PT (2) | PT1790346E (enExample) |
| UA (1) | UA78699C2 (enExample) |
| WO (1) | WO2002083147A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL142650A (en) * | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| US8975246B2 (en) | 2001-04-17 | 2015-03-10 | Galmed Research And Development Ltd. | Bile acid or bile salt fatty acid conjugates |
| TR201901012T4 (tr) * | 2007-07-25 | 2019-02-21 | Univ Graz Medizinische | Arteriosklerozun tedavisinde nor-safra asitlerinin kullanımı. |
| US8470885B2 (en) * | 2009-01-12 | 2013-06-25 | Biokier, Inc. | Composition and method for treatment of diabetes |
| US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
| US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
| WO2010086864A1 (en) | 2009-02-02 | 2010-08-05 | Galmed International Ltd. | Methods and compositions for treating alzheimer's disease |
| US20120202890A1 (en) | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
| WO2013166176A1 (en) * | 2012-05-01 | 2013-11-07 | Catabasis Pharmaceuticals, Inc. | Fatty acid conjugates of statin and fxr agonists; compositions and method of uses |
| CN103571617A (zh) * | 2012-07-26 | 2014-02-12 | 丰益(上海)生物技术研发中心有限公司 | 改进的动物油脂加工工艺 |
| ES2701077T3 (es) | 2012-11-29 | 2019-02-20 | St Pharm Co Ltd | Conjugado de oligómero de ácido biliar para un nuevo transporte vesicular y uso del mismo |
| IL227890A0 (en) * | 2013-08-08 | 2014-01-30 | Galderm Therapeutics Ltd | Antiaging compounds containing bile acid and fatty acid conjugates |
| WO2016199137A1 (en) * | 2015-06-10 | 2016-12-15 | Galmed Research And Development Ltd. | Low dose compositions of aramchol salts |
| HUE045209T2 (hu) * | 2013-12-04 | 2019-12-30 | Galmed Res & Development Ltd | Aramchol-sók |
| US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| EP3148549A4 (en) * | 2014-06-01 | 2017-11-15 | Galmed Research and Development Ltd. | Fatty acid bile acid conjugates for treatment of lipodystrophy |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| CN116687850A (zh) | 2022-02-24 | 2023-09-05 | 甘莱制药有限公司 | 包含环状膦酸酯化合物的药物组合物及其制备方法与用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3859437A (en) * | 1972-06-02 | 1975-01-07 | Intellectual Property Dev Corp | Reducing cholesterol levels |
| US3856953A (en) * | 1973-05-15 | 1974-12-24 | Intellectual Property Dev Corp | Method of treating fatty liver |
| IT1167479B (it) * | 1981-07-24 | 1987-05-13 | Carlo Scolastico | Derivati dell'acido chenodesossicolico |
| IT1167478B (it) * | 1981-07-24 | 1987-05-13 | Carlo Scolastico | Derivati dell'acido ursodesossicolico |
| JPS6164701A (ja) * | 1984-09-06 | 1986-04-03 | Meito Sangyo Kk | カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用 |
| DE3930696A1 (de) * | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| US5278320A (en) * | 1992-09-11 | 1994-01-11 | Merck & Co., Inc. | Cholesterol lowering compounds produced by directed biosynthesis |
| DE4432708A1 (de) * | 1994-09-14 | 1996-03-21 | Hoechst Ag | Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung |
| KR20010031501A (ko) * | 1997-10-31 | 2001-04-16 | 추후제출 | 5-알파 환원효소 활성을 조절하는 방법 및 조성물 |
| US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| IL142650A (en) * | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| IL123998A (en) * | 1998-04-08 | 2004-09-27 | Galmed Int Ltd | Conjugates of bile salts and pharmaceutical preparations containing them |
| US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| JP2006306800A (ja) * | 2005-04-28 | 2006-11-09 | Kirin Brewery Co Ltd | ファルネソイドｘ受容体活性化剤 |
-
2001
- 2001-04-17 IL IL142650A patent/IL142650A/en active IP Right Grant
-
2002
- 2002-04-15 DK DK02761957T patent/DK1379254T3/da active
- 2002-04-15 DK DK07002485T patent/DK1790346T3/da active
- 2002-04-15 AT AT07002485T patent/ATE432705T1/de not_active IP Right Cessation
- 2002-04-15 EP EP07002485A patent/EP1790346B1/en not_active Expired - Lifetime
- 2002-04-15 AU AU2002307771A patent/AU2002307771B2/en not_active Expired
- 2002-04-15 CZ CZ2008296A patent/CZ309042B6/cs not_active IP Right Cessation
- 2002-04-15 PT PT07002485T patent/PT1790346E/pt unknown
- 2002-04-15 EA EA200301017A patent/EA007565B1/ru not_active IP Right Cessation
- 2002-04-15 ES ES02761957T patent/ES2289137T3/es not_active Expired - Lifetime
- 2002-04-15 MX MXPA03009553A patent/MXPA03009553A/es active IP Right Grant
- 2002-04-15 DE DE60220775T patent/DE60220775T2/de not_active Expired - Lifetime
- 2002-04-15 CA CA2703688A patent/CA2703688C/en not_active Expired - Lifetime
- 2002-04-15 PL PL366585A patent/PL205057B1/pl unknown
- 2002-04-15 CA CA2444266A patent/CA2444266C/en not_active Expired - Lifetime
- 2002-04-15 HU HU0400801A patent/HU230548B1/hu unknown
- 2002-04-15 PT PT02761957T patent/PT1379254E/pt unknown
- 2002-04-15 PL PL387458A patent/PL211438B1/pl unknown
- 2002-04-15 WO PCT/IL2002/000303 patent/WO2002083147A1/en not_active Ceased
- 2002-04-15 AT AT02761957T patent/ATE365044T1/de active
- 2002-04-15 CZ CZ20032710A patent/CZ300489B6/cs not_active IP Right Cessation
- 2002-04-15 ES ES07002485T patent/ES2328966T3/es not_active Expired - Lifetime
- 2002-04-15 CN CNB028081870A patent/CN1259918C/zh not_active Expired - Lifetime
- 2002-04-15 US US10/474,032 patent/US7501403B2/en not_active Expired - Lifetime
- 2002-04-15 UA UA2003109404A patent/UA78699C2/uk unknown
- 2002-04-15 BR BR0208924-6A patent/BR0208924A/pt not_active Application Discontinuation
- 2002-04-15 JP JP2002580951A patent/JP4324706B2/ja not_active Expired - Lifetime
- 2002-04-15 KR KR1020037013339A patent/KR100883080B1/ko not_active Expired - Lifetime
- 2002-04-15 NZ NZ528868A patent/NZ528868A/en not_active IP Right Cessation
- 2002-04-15 DE DE60232559T patent/DE60232559D1/de not_active Expired - Lifetime
- 2002-04-15 EP EP02761957A patent/EP1379254B1/en not_active Expired - Lifetime
-
2003
- 2003-10-15 NO NO20034609A patent/NO333910B1/no not_active IP Right Cessation
-
2007
- 2007-01-19 AU AU2007200191A patent/AU2007200191B2/en not_active Expired
- 2007-09-07 CY CY20071101160T patent/CY1106853T1/el unknown
-
2009
- 2009-01-28 US US12/361,291 patent/US8110564B2/en not_active Expired - Lifetime
-
2013
- 2013-09-10 NO NO20131219A patent/NO335087B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2289137T3 (es) | Utilizacion de conjugados de acido o acidos grasos con un acido biliar o una sal biliar. | |
| ES2871117T3 (es) | Procedimientos para modular la microbiota intestinal | |
| JP2022541582A (ja) | 自己免疫障害を処置するための組成物および方法 | |
| AU2016346304B2 (en) | Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders | |
| PT100629A (pt) | Metodo para a estimulacao da resposta imune usando hormona de crescimento | |
| Bürger et al. | C‐reactive protein—a characteristic feature of health control in swine | |
| AU2002307771A1 (en) | Use of bile acid or bile salt fatty acid conjugates | |
| CN109414474B (zh) | 肝脏、胆道和胰腺障碍的治疗 | |
| Leem et al. | Effects of egg yolk proteins on the longitudinal bone growth of adolescent male rats | |
| US12419950B2 (en) | Saponin-based vaccine adjuvants | |
| BR112015015611B1 (pt) | Composições de iga secretora e sua utilização | |
| ES2913336T3 (es) | Métodos de uso de IgA secretora | |
| JP2012518641A (ja) | 脂肪腫および脂肪肉腫を治療する方法 | |
| BR102023013650A2 (pt) | Peptídeo de gnrh modificado e seu conjugado para imunocastração de mamíferos, método de fabricação, composição e kit | |
| JP2000219638A (ja) | アジュバントおよびそれを用いたワクチン | |
| Bezeau | LA REVUE VETERINAIRE CANADIENNE |